BACTOCILL IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Bactocill In Plastic Container, and when can generic versions of Bactocill In Plastic Container launch?

Bactocill In Plastic Container is a drug marketed by Baxter Hlthcare and is included in one NDA.

The generic ingredient in BACTOCILL IN PLASTIC CONTAINER is oxacillin sodium. There are thirty-eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the oxacillin sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Bactocill In Plastic Container

A generic version of BACTOCILL IN PLASTIC CONTAINER was approved as oxacillin sodium by SAGENT PHARMS on March 30^th, 2012.

Summary for BACTOCILL IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	61
Clinical Trials:	1
Patent Applications:	19
DailyMed Link:	BACTOCILL IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for BACTOCILL IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cubist Pharmaceuticals LLC	Phase 2

See all BACTOCILL IN PLASTIC CONTAINER clinical trials

Pharmacology for BACTOCILL IN PLASTIC CONTAINER

Drug Class

Penicillin-class Antibacterial

US Patents and Regulatory Information for BACTOCILL IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	BACTOCILL IN PLASTIC CONTAINER	oxacillin sodium	INJECTABLE;INJECTION	050640-001	Oct 26, 1989		RX	Yes	Yes
Baxter Hlthcare	BACTOCILL IN PLASTIC CONTAINER	oxacillin sodium	INJECTABLE;INJECTION	050640-002	Oct 26, 1989		RX	Yes	Yes

Last updated: July 25, 2026

Market dynamics and financial trajectory for BACTOCILL (in plastic container)

Executive summary: BACTOCILL in plastic container is a branded formulation of bacampicillin (oral). Market dynamics are dominated by (1) longstanding generic competition for bacampicillin products, (2) low likelihood of sustained pricing power once multiple multisource generics establish, and (3) supply-channel inertia tied to packaging format approvals and contract pharmacy distribution. Financial trajectory tracks broader “old antibiotic” economics: modest, declining unit share post-generic entry, intermittent revenue support from packaging-specific procurement, and continued pressure from margin compression and wholesaler pass-through.

BACTOCILL in plastic container is best treated as a packaging/market-communication variant rather than a distinct pharmacologic product line. Revenue is therefore sensitive to procurement cycles, tender specifications that reference container type, and substitution allowances in payer formularies and pharmacy contracts.

---

What is BACTOCILL in plastic container and how does bacampicillin fit the antibiotic market?

BACTOCILL in plastic container is an oral bacampicillin brand product. Bacampicillin is a prodrug of ampicillin, used for bacterial infections where aminopenicillin activity is appropriate.

Where it sits in the market

• Therapeutic class: aminopenicillin antibiotic
• Clinical positioning: outpatient and step-down use for susceptible organisms; limited “new” demand drivers compared with newer stewardship-targeted agents
• Competitive set: multisource bacampicillin generics; competing aminopenicillin formats (ampicillin-class products) and other β-lactams based on local formulary preference and price

Demand profile characteristics

• Stable but limited addressable population driven by general infection epidemiology
• Downward pressure from antibiotic stewardship protocols that restrict broad use and favor narrower-spectrum agents when appropriate
• Substitution dynamics: generics typically capture most volume once available, making branded packaging less price elastic than clinical alternatives

---

Who sells BACTOCILL in plastic container and what is the competitive landscape?

Featured competitive structure for bacampicillin

• Branded originator: BACTOCILL
• Primary competition: generic bacampicillin oral tablets/capsules (depending on country)
• Secondary competition: other β-lactam antibiotics including amoxicillin/ampicillin derivatives, depending on local guidelines and procurement pricing

How packaging changes the competitive set

• “In plastic container” typically matters at the channel and procurement level. It does not materially change clinical efficacy.
• It can, however, influence:
  • Tender compliance (exact NDC and packaging description)
  • Automated dispensing system compatibility
  • Retail dispensing preference where package presentation reduces handling errors

Market outcome typical for such variants

• Generics with equivalent dosage form and content compete primarily on price
• Branded packaging variants can retain small incremental shelf and contract share if procurement specifications explicitly reference the packaging presentation

---

What market dynamics drive pricing, volume, and contract wins for bacampicillin?

For older oral antibiotics like bacampicillin, the market is shaped by five mechanics:

1. Generic substitution ceiling

   • Once multiple generics enter, branded products rarely sustain premium pricing across most channels.
   • Revenue becomes a function of protected niches: contracts with explicit packaging specs, limited formulary exceptions, or inventory timing.

2. Wholesaler and distributor buying behavior

   • Distributors often shift to lowest net price after replenishment cycles.
   • Packaging-specific identifiers can slow substitution, but typically only temporarily.

3. Payer and pharmacy formulary handling

   • Formularies generally list active ingredient equivalence and route to lowest-cost therapeutics.
   • Pharmacy contracts commonly allow substitution among rated equivalents.

4. Stewardship and guideline consumption

   • Prescribing patterns shift toward narrower-spectrum agents for many indications.
   • That shifts total category demand even if bacampicillin’s place remains.

5. Product integrity and logistics

   • Packaging can matter for moisture/handling requirements, particularly for solid oral dosage forms.
   • “Plastic container” procurement can reflect supply-chain standardization and reduced damage rates versus alternative formats.

Net effect: The product line tends to see:

• Declining branded unit volume after generic proliferation
• Revenue volatility driven by contract timing rather than clinical demand acceleration
• Margin compression as net pricing falls

---

When does BACTOCILL face generic erosion and how do exclusivity dynamics translate to revenue?

Market-level exclusivity reality

• For bacampicillin, the branded period is largely historical in most markets where generics exist.
• Packaging variants can persist in catalog, but do not usually extend meaningful IP or regulatory exclusivity.

Revenue implications

• Branded revenues typically transition through phases:
  1. Pre-generic dominance: premium pricing and stable share
  2. Initial generic entry: sharp share loss; branded net price declines
  3. Multisource normalization: share loss stabilizes at a low branded level unless specific contract protections exist
  4. Packaging-specific niche aging: any packaging-driven retention erodes over time as generics adopt equivalent packaging standards

How to interpret “in plastic container”

• It often correlates with specific distribution requirements or retail dispensing standards.
• That can delay complete replacement but usually does not stop it.

---

What is the financial trajectory pattern for older branded oral antibiotics under generic pressure?

Typical financial trajectory

• Sales peak early (brand maturity period)
• Long decline as generics expand
• Flattening at a low level if:
  • procurement specifies branded packaging
  • supply constraints or formulary inertia persists
  • the brand maintains acceptable net pricing for certain accounts

Key drivers of month-to-month revenue

• Contract replenishment schedules
• Inventory alignment before tenders
• Competitive price changes by generic manufacturers
• Wholesale order patterns (pull-through vs push-through)

Outcome expectation

• Without a new clinical differentiation or meaningful regulatory exclusivity, the trajectory is usually:
  • declining gross revenue
  • declining branded gross margin
  • limited growth offsets except through packaging-specified contracts

---

What do data-backed revenue risks look like for BACTOCILL in plastic container?

For business planning, the risk map is straightforward:

• High substitution risk: bacampicillin is an established molecule with generic availability in many jurisdictions.
• Price erosion risk: branded premiums fall quickly once equivalent multisources are widely used.
• Contract fragility risk: packaging-specific SKUs can lose shelf and contract position when procurement standards update.
• Supply-chain swap risk: when generic manufacturers offer plastic-container equivalents at lower net prices, the branded packaging advantage becomes irrelevant.

Financial exposure

• Revenue is exposed primarily through:
  • unit share loss
  • net price compression
  • discontinuation of branded packaging if manufacturer rationalizes product portfolios

---

What role do FDA status, Orange Book listings, and AB-rated generic labeling play?

For US market dynamics, the legal-regulatory structure is typically:

• Orange Book controls: whether bacampicillin brand has listed patents covering active ingredient, formulation, or methods
• AB-rated generics: FDA approvals that allow therapeutic equivalence substitution at the pharmacy level
• Labeling and dispensing: packaging format may be encoded in NDC and product presentation, influencing substitution mechanics

If the branded drug has no unexpired listed patents tied to relevant packaging or formulation, then competitive entry and substitution are largely non-negotiable at the channel level.

How this translates to “plastic container”

• A packaging-only difference often does not block generic substitution if the dosage form and route are the same and the generic meets equivalence standards.
• The remaining advantage is logistical, not regulatory.

---

How does “in plastic container” affect product switching, NDC behavior, and channel economics?

Channel economics impact

• Plastic-container packaging can be preferred by certain retail and institutional channels due to handling and dispensing compatibility.
• That can influence:
  • reorder timing
  • automated sorting and shelf-ready processes
  • inventory management for pharmacies and clinics

Switching dynamics

• Generic substitution is often immediate once the generic’s presentation matches procurement specs.
• If a multisource generic initially uses a different packaging format, the switch can be delayed until that competitor adds equivalent packaging.

Result

• Revenue decline can show step-changes correlated with when preferred packaging alternatives become available.

---

What formulation and container-patent barriers could protect the brand?

For packaging-focused SKUs, barriers are usually narrow:

• Formulation patents: protect changes in composition, excipients, release characteristics
• Method-of-use patents: protect dosing regimens or therapeutic uses
• Container/presentation patents: only protect if the packaging structure and its regulatory claims are directly patented and still valid

Practical market outcome

• Many older antibiotic brands do not retain enforceable, high-value IP that meaningfully covers container format.
• As a result, “plastic container” typically does not create durable legal protection.

---

How strong are the patent estate and what does that imply for long-run revenue?

Long-run revenue logic for older oral antibiotics

• Brand revenue durability requires at least one of:
  • enforceable patent coverage that blocks equivalent generics
  • enforceable formulation differentiation recognized by regulators and prescribers
  • strong procurement entrenchment tied to unique presentation with no equivalent substitute

For bacampicillin products, the usual industry outcome is that enforcement becomes irrelevant once generic equivalents reach market scale.

Implication

• The brand’s long-run value is tied more to procurement and distribution inertia than to patent estate strength.

---

What Paragraph IV and biosimilar risks apply, and why?

• Biosimilar risk: does not apply because bacampicillin is not a biologic.
• Paragraph IV risk: applies only if relevant US Orange Book patents exist and generics attempt at-risk entry against listed patents.

Business implication for the “in plastic container” SKU

• If patents do not exist or have expired for relevant claims, then the risk event is not Paragraph IV litigation but standard generic substitution.

---

What generic launch scenarios exist for bacampicillin and how would they hit revenues?

Scenario A: immediate multisource equivalence

• Multiple generics already sell in matching dosage form and often matching packaging standard.
• Revenue impact: rapid share and net price erosion, minimal branded tail.

Scenario B: packaging mismatch during early entry

• Generics enter with different bottle/container types or NDC presentations.
• Revenue impact: delayed switching, but continued decline.

Scenario C: contract-driven retention

• Specific institutions specify exact presentation.
• Revenue impact: localized retention and slower decline in those accounts; category-level erosion continues.

Scenario D: supply rationalization

• Branded manufacturer reduces SKU count or changes packaging.
• Revenue impact: step-function loss where the brand no longer meets tender or local inventory specs.

---

Which companies are likely competitive threats to BACTOCILL in plastic container?

In bacampicillin markets, competitive threats typically include:

• Generic manufacturers producing bacampicillin oral solid dosage forms
• Distributors and pharmacy chains that steer to lowest-cost equivalents
• Alternative β-lactam producers (amoxicillin-class) that compete on formulary position

Threat profile

• Largest threat is lowest net price among therapeutically equivalent generics.
• Packaging equivalence becomes a secondary switch criterion once price is competitive.

---

How does BACTOCILL compare with other bacampicillin presentations or brands in the same therapeutic class?

Comparison logic

• If other bacampicillin products are bioequivalent and dose-equivalent, pricing and packaging presentation drive differentiation.
• If other brands or generics use different bottle materials or labeling formats, the clinical impact is nil and switching is channel-dependent.

Business takeaway

• Any “container” differentiation is typically short-lived because packaging is a controllable supply-chain parameter for generic manufacturers.

---

What commercialization levers determine whether revenue stabilizes or continues to decline?

For a branded old antibiotic SKU, levers are limited:

• Pricing strategy: maintain acceptable net pricing for high-volume accounts
• Contracting: secure supply agreements with explicit packaging specs
• Forecast accuracy: avoid stock-outs that create permanent substitution
• Packaging standardization: align container type with dominant channel requirements
• Formulary management: support restricted niches where substitution is constrained

Expected outcome without IP reinforcement

• Revenue stabilization requires contracting or distribution niches, not clinical differentiation.

---

Key Takeaways

• BACTOCILL in plastic container is a bacampicillin brand variant where channel and packaging specifications matter more than clinical differentiation.
• Market dynamics are dominated by generic substitution, net price compression, and procurement-driven shelf positioning.
• The financial trajectory for older oral antibiotics under generic pressure is typically declining revenue with potential step-changes tied to packaging-equivalent generic availability and contract timing.
• Biosimilar risk is not applicable; Paragraph IV risk applies only if unexpired, relevant US Orange Book patents exist for the formulation or presentation claims.
• Long-run brand value is most likely to persist only through localized contracting and packaging entrenchment, not patent-protected uniqueness.

---

FAQs

1) Does “plastic container” prevent generic substitution for bacampicillin products?
No, not if generics are approved as therapeutically equivalent and meet the same dosage form and strength requirements. Packaging identity usually affects procurement timing rather than legal substitutability.

2) What tends to happen to branded bacampicillin sales once multiple generic manufacturers enter?
Sales typically decline as pharmacies and distributors shift to lower net price multisources, with branded revenue stabilizing only in packaging-specified contract niches.

3) Are there biosimilar risks for BACTOCILL?
No. Bacampicillin is not a biologic, so biosimilar frameworks do not apply.

4) What drives step-changes in revenue for older branded antibiotic SKUs?
Tender/contract cycles, inventory alignment, and the timing when generics offer equivalent packaging presentations.

5) What commercialization actions most affect remaining brand share in a mature generic market?
Securing supply agreements with explicit presentation requirements and maintaining reliable availability to avoid substitution opportunities.

---

References

1. US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA Orange Book database).
2. FDA. Approved Drug Products: Therapeutic Equivalence Evaluations (AB rating concept; FDA guidance and Orange Book listings). (Accessed via FDA resources).